This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Sage Therapeutics Stock (NASDAQ:SAGE) Get Sage Therapeutics alerts:Sign Up Key Stats Today's Range$8.68▼$8.6850-Day Range$8.68▼$9.2852-Week Range$6.35▼$9.36VolumeN/AAverage Volume2.32 million shsMarket Capitalization$543.54 millionP/E RatioN/ADividend YieldN/APrice Target$9.37Consensus RatingHold Company Overview Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Read More Sage Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreSAGE MarketRank™: Sage Therapeutics scored higher than 11% of companies evaluated by MarketBeat, and ranked 819th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingHold Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Sage Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageSage Therapeutics has received no research coverage in the past 90 days.Read more about Sage Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($3.52) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SAGE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for SAGE on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sage Therapeutics' insider trading history. Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SAGE Stock News HeadlinesFormer Sage Therapeutics executives launch neurology biotech with $106MApril 21, 2026 | bizjournals.comTortugas debuts with $106M and brain drugs from Hansoh, EisaiApril 21, 2026 | finance.yahoo.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 6 at 1:00 AM | Weiss Ratings (Ad)Supernus a new buy at BofA on 'underappreciated' CNS assetsOctober 29, 2025 | seekingalpha.comBiogen’s Zurzuvae approved as first postpartum depression drug in EuropeSeptember 18, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric PortfolioSeptember 2, 2025 | finance.yahoo.comUK Regulator Approves Biogen’s Drug For Treating Postnatal DepressionAugust 27, 2025 | msn.comReunion’s psychedelic drug headed to late-stage testingAugust 18, 2025 | yahoo.comSee More Headlines SAGE Stock Analysis - Frequently Asked Questions How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Wednesday, July, 30th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($0.96) by $0.17. The firm's quarterly revenue was up 266.0% on a year-over-year basis. When did Sage Therapeutics IPO? Sage Therapeutics (SAGE) raised $90 million in an initial public offering on Friday, July 18th 2014. The company issued 5,000,000 shares at a price of $18.00 per share. What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings7/30/2025Today5/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SAGE's financial health is in the Green zone, according to TradeSmith. SAGE has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAGE CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees690Year Founded2010Price Target and Rating Average Price Target for Sage Therapeutics$9.37 High Price Target$12.00 Low Price Target$8.50 Potential Upside/Downside+7.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$400.67 million Net Margins-427.78% Pretax Margin-427.78% Return on Equity-67.10% Return on Assets-58.42% Debt Debt-to-Equity RatioN/A Current Ratio9.16 Quick Ratio9.13 Sales & Book Value Annual Sales$41.24 million Price / Sales13.18 Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book1.47Miscellaneous Outstanding Shares62,620,000Free Float59,177,000Market Cap$543.54 million OptionableOptionable Beta0.26 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:SAGE) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredMilitary ‘Dark Energy’ to Power AIWhen it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...Altimetry | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SAGE Stock Alerts